Related Experiment Video

Updated: Jun 3, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Lipogenic enzymes as therapeutic targets for obesity and diabetes

James M Lenhard1

  • 1Cardiovascular and Metabolic Research, Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Springhouse, PA 19477, USA. Jlenhar1@its.jnj.com

Current Pharmaceutical Design
|March 8, 2011
PubMed

Insights

Researchers are exploring lipid-metabolizing enzymes in adipose tissue as drug targets for obesity and type II diabetes. Inhibiting key enzymes like acetyl-CoA carboxylase reduces fat storage and may boost energy expenditure.

Area of Science:

  • Biochemistry
  • Metabolic diseases
  • Pharmacology

Background:

  • Excess fat storage in peripheral tissues contributes to obesity and type II diabetes.
  • Adipose tissue's lipid-metabolizing enzymes are key targets for therapeutic intervention.
  • Cultured cell lines and stem cells facilitate research into fat metabolism.

Purpose of the Study:

  • To review pharmaceutical research on lipid-metabolizing enzymes in adipose tissue.
  • To highlight the role of these enzymes in fat metabolism and potential therapeutic strategies.
  • To discuss enzyme inhibitors as a means to reduce excess fat storage.

Main Methods:

  • Focus on enzymes regulating lipogenesis: acetyl-CoA carboxylase, fatty acid synthase, diacylglycerol acyl transferase, and stearoyl CoA desaturase.
  • Utilizing preadipocytes and adipocytes to study enzyme function and inhibition.
  • Monitoring protein expression to confirm adipogenesis.

Main Results:

  • Inhibition of key lipogenic enzymes reduces fat cell differentiation and lipid synthesis.
  • Targeting these enzymes may lead to increased fat oxidation and energy expenditure.
  • Pharmaceutical research is actively developing inhibitors for these targets.

Conclusions:

  • Lipid-metabolizing enzymes in adipose tissue are promising drug targets for metabolic diseases.
  • Inhibitor development shows potential for reducing obesity and type II diabetes.
  • Further research into adipose tissue metabolism can yield novel therapeutic approaches.

More Related Videos

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function09:20

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

Related Concept Videos

Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...